Can a combination of standard drugs, a PARP inhibitor, and intensity modulated radiation therapy to slow pancreatic tumor growth?
A chemoradiation clinical trial tests standard chemotherapy plus an anti-malaria drug and compares two types of radiation treatments, to slow tumor growth.
Researchers are testing a new combination of chemotherapies and radiation to shrink pancreatic cancer tumors and make surgical removal possible.
Does adding a PARP inhibitor drug to standard treatment help control the spread of advanced pancreatic cancer in patients with the BRCA mutation?
A clinical trial tests the effectiveness of an approved colon cancer drug against advanced pancreatic neuroendocrine cancer.
A clinical trial tests whether a malaria drug can make standard chemotherapy for advanced pancreatic cancer more effective.
A clinical trial compares two chemotherapy regimens to see which one is more effective at knocking out remaining cancer cells.
For patients with stable metastatic pancreatic cancer, a clinical trial compares standard chemotherapy with immunotherapy.
A clinical trial seeks pancreatic cancer patients with the MSI (microsatellite instability) genetic signature, to test an immunotherapy drug.
A clinical trial uses a new immunotherapy drug in combination with standard chemotherapy drugs in metronomic therapy to treat metastatic pancreatic cancer.
Gene therapy combined with standard first-line chemotherapy treatment forms a clinical trial for metastatic pancreatic cancer.